Details for Patent: 8,158,616

Which drugs does patent 8,158,616 protect, and when does it expire?

Patent 8,158,616 protects OLUMIANT and is included in one NDA.

This patent has fifty-seven patent family members in forty-four countries.

Summary for Patent: 8,158,616

Title:	Azetidine and cyclobutane derivatives as JAK inhibitors
Abstract:	The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Voorhees, NJ)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	12/401,348
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,158,616
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,158,616

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019		RX	Yes	No			Y	Y
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	No			Y	Y
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-003	May 10, 2022		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,158,616

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070828
Australia	2009223640
Brazil	PI0909040
Canada	2718271
Chile	2009000576
China	102026999
China	103788098